Loading...
Market
What will be the outcome of Vaxcyte's Phase 3 trial for VAX-31 by December 31, 2024?
2
Resolution / Starting Odds
Exceeds regulatory criteria • 25%
Meets regulatory criteria • 25%
Fails to meet regulatory criteria • 25%
Trial delayed or inconclusive • 25%
Official trial results published by Vaxcyte
Story
Vaxcyte ($PCVX) Shares Surge 33% on Positive Pneumococcal Vaccine Data
Sep 3, 2024, 12:25 PM
Vaxcyte ($PCVX) has reported positive topline data from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in adults aged 50 and older. The data indicated that VAX-31 met or exceeded regulatory immunogenicity criteria at high and middle doses. Following this announcement, Vaxcyte's shares surged 33% in pre-market trading. The vaccine's safety profile was found to be similar to Pfizer's pneumococcal shot. VAX-31 aims to prevent invasive pneumococcal disease.
View original story
Similar markets
Phase 3 trial initiation • 25%
FDA Breakthrough Therapy designation • 25%
Partnership announcement • 25%
No major milestone • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $5 billion • 25%
$5 billion to $6 billion • 25%
$6 billion to $7 billion • 25%
Above $7 billion • 25%
Below $10 billion • 25%
$10 billion - $15 billion • 25%
$15 billion - $20 billion • 25%
Above $20 billion • 25%
Below $100 • 25%
$100 to $120 • 25%
$120 to $140 • 25%
Above $140 • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive - Significant survival improvement • 25%
Neutral - No significant difference • 25%
Negative - Worse outcomes • 25%
Trial inconclusive • 25%